Literature DB >> 29605531

High prevalence of ceftriaxone resistance among invasive Salmonella enterica serotype Choleraesuis isolates in Thailand: The emergence and increase of CTX-M-55 in ciprofloxacin-resistant S. Choleraesuis isolates.

Sirirat Luk-In1, Tanittha Chatsuwan2, Chaiwat Pulsrikarn3, Aroon Bangtrakulnonth3, Ubolrat Rirerm4, Wanla Kulwichit5.   

Abstract

S. Choleraesuis is a highly invasive zoonotic pathogen that causes a serious systemic infection in humans. The emergence and increase of resistance to ceftriaxone and ciprofloxacin among S. Choleraesuis has become a serious therapeutic problem. The present study demonstrated high frequency of antimicrobial resistance in Salmonella Choleraesuis among 414 nontyphoidal Salmonella isolates from bacteremic patients in Thailand. High rates of ceftriaxone (58.3%) and ciprofloxacin (19.6%) resistances were observed in S. Choleraesuis isolates. The dissemination of the self-transferable blaCTX-M-14-carrying IncFIIs, IncFII, and IncI1 plasmids and blaCMY-2-carrying IncA/C plasmid along with the clonal spread of blaCMY-2-harbouring S. Choleraesuis isolates contributed to the high frequency of resistance to extended-spectrum cephalosporins (ESCs; third- and fourth-generation cephalosporins) during 2005-2007. We reported the first occurrence of ceftazidime-hydrolysing CTX-M-55 in S. Choleraesuis isolates which dramatically increased and became the most abundant CTX-M variant among ESC-resistant S. Choleraesuis isolates during 2012-2016. The spread of clone pulsotype B3 was due to the dissemination of IncA/C plasmids carrying both blaCTX-M-55 and qnrS1 among ciprofloxacin-resistant S. Choleraesuis isolates harbouring D87G in GyrA. These isolates were apparently responsible for the high rates of co-resistance to ESCs and ciprofloxacin (51.3%) during 2012-2016. This study emphasizes the importance to have an action plan to control the dissemination of antimicrobial resistance in S. Choleraesuis since this poses a threat to global health due to travel and trade in animal food products.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Bacteremia; CTX-M-55; Ceftriaxone; Ciprofloxacin; Salmonella enterica

Mesh:

Substances:

Year:  2018        PMID: 29605531     DOI: 10.1016/j.ijmm.2018.03.008

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  10 in total

1.  Epidemiological Study on Prevalence, Serovar Diversity, Multidrug Resistance, and CTX-M-Type Extended-Spectrum β-Lactamases of Salmonella spp. from Patients with Diarrhea, Food of Animal Origin, and Pets in Several Provinces of China.

Authors:  Wei Wang; Li Zhao; Yujie Hu; Tania Dottorini; Séamus Fanning; Jin Xu; Fengqin Li
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

2.  Prevalence of Chromosomally Located blaCTX-M-55 in Salmonella Typhimurium ST34 Isolates Recovered from a Tertiary Hospital in Guangzhou, China.

Authors:  Shihan Zeng; Zhenxu Zhuo; Yulan Huang; Jiajun Luo; Yulian Feng; Baiyan Gong; Xiyi Huang; Aiwu Wu; Chao Zhuo; Xiaoyan Li
Journal:  Microbiol Spectr       Date:  2022-05-26

3.  In Vitro Susceptibility of Typhoidal, Nontyphoidal, and Extended-Spectrum-β-Lactamase-Producing Salmonella to Ceftolozane/Tazobactam.

Authors:  Jade L L Teng; Elaine Chan; Asher C H Dai; Gillian Ng; Tsz Tuen Li; Christopher Lai; Alan K L Wu; Susanna K P Lau; Patrick C Y Woo
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

4.  Molecular epidemiology and antimicrobial resistance of invasive non-typhoidal Salmonella in China, 2007-2016.

Authors:  Zeqiang Zhan; Xuebin Xu; Zhen Gu; Jianghong Meng; Xiayidan Wufuer; Mingliu Wang; Meilian Huang; Jianhui Chen; Chunmei Jing; Zhiying Xiong; Mei Zeng; Ming Liao; Jianmin Zhang
Journal:  Infect Drug Resist       Date:  2019-09-12       Impact factor: 4.003

5.  Emergence and Evolution of High-Level Cephalosporin-Resistant Salmonella Goldcoast in Northern Taiwan.

Authors:  Ye Feng; Yi-Jung Chang; Szu-Hsuan Fang; Lin-Hui Su; Hsin-Chieh Li; Hsin-Ping Yang; Min-Jia Yu; Cheng-Hsun Chiu
Journal:  Open Forum Infect Dis       Date:  2019-12-17       Impact factor: 3.835

6.  Serotypes and antimicrobial resistance profiles of Salmonella enterica recovered from clinical swine samples.

Authors:  Siriporn Kongsoi; Suksun Chumsing; Darunee Satorn; Panisa Noourai
Journal:  Vet World       Date:  2020-11-03

7.  Nonspecific protection of heat-inactivated Mycobacterium bovis against Salmonella Choleraesuis infection in pigs.

Authors:  Rita Vaz-Rodrigues; Elisa Ferreras-Colino; María Ugarte-Ruíz; Michele Pesciaroli; Jobin Thomas; Teresa García-Seco; Iker A Sevilla; Marta Pérez-Sancho; Rafael Mateo; Lucas Domínguez; Christian Gortazar; María A Risalde
Journal:  Vet Res       Date:  2022-04-18       Impact factor: 3.829

8.  Dynamics of Antimicrobial Resistance and Genomic Epidemiology of Multidrug-Resistant Salmonella enterica Serovar Indiana ST17 from 2006 to 2017 in China.

Authors:  Pengcheng Du; Xiaobin Liu; Yue Liu; Ruichao Li; Xin Lu; Shenghui Cui; Yongning Wu; Séamus Fanning; Li Bai
Journal:  mSystems       Date:  2022-07-21       Impact factor: 7.324

9.  Occurrence of mcr-mediated colistin resistance in Salmonella clinical isolates in Thailand.

Authors:  Sirirat Luk-In; Tanittha Chatsuwan; Naris Kueakulpattana; Ubolrat Rirerm; Dhammika Leshan Wannigama; Rongpong Plongla; Ratana Lawung; Chaiwat Pulsrikarn; Siriporn Chantaroj; Pattharaporn Chaichana; Nattida Saksaengsopa; Teerarat Shanthachol; Malee Techapornroong; Sunee Chayangsu; Wanla Kulwichit
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

10.  A Salmonella enterica subspecies enterica serovar Choleraesuis outbreak in weaned piglets in Serbia: clinical signs, pathologic changes, and microbiologic features.

Authors:  Bozidar Savic; Nemanja Zdravkovic; Oliver Radanovic; Nemanja Jezdimirovic; Branislav Kureljusic; Ognjen Stevancevic
Journal:  J Vet Diagn Invest       Date:  2021-07-08       Impact factor: 1.569

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.